Clinical Trials

Uveal melanoma is a rare type of eye cancer. Less than 2,000 people are diagnosed with the disease annually in the United States. It is treatable, however, roughly half of uveal melanoma patients will develop metastatic disease, most commonly to the liver, drastically reducing their chance for survival.

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.

Personalized cancer vaccines to treat cancer are an emerging area of cancer research.

Treatment with the novel immunotherapy PV-10 led to hepatic responses in patients with metastatic uveal melanoma with liver metastases, according to updated data from a phase 1 trial.